Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD

Documenti analoghi

• Large‐Scale Plasma Proteomics Identifies Early Molecular Deviations and Improves Risk Prediction for Heart Failure Among Individuals With Obesity
  di: Maohua Li, et al.
  Pubblicazione: (2026)
• Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD
  di: Yuanping Shi, et al.
  Pubblicazione: (2026)
• Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases
  di: Xinxuan Li, et al.
  Pubblicazione: (2026)
• Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A Literature Review on Pathophysiology and Treatment
  di: Michael Romanos, et al.
  Pubblicazione: (2026)
• Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts
  di: Hongmei Zhang, et al.
  Pubblicazione: (2026)